About 4 results found for searched term "VX-150" (0.123 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M4980 | Decernotinib | JAK |
| VX-509; VRT-831509 | ||
| Decernotinib is a potent and selective Janus kinase 3 (JAK3) inhibitor with Ki of 2.5 nM; IC50 is 50-170 nM in cellular assays. | ||
| M20814 | VX-150 | Sodium Channel |
| EOS-62073 | ||
| VX-150 (EOS-62073) is an orally bioavailable pro-drug that rapidly converts into its active moiety, which is a highly selective inhibitor of NaV1.8 relative to the other sodium channel subtypes (>400-fold). | ||
| M10852 | M-4344 | Others |
| VX-803 (M4344, ATR inhibitor 2) is a selective inhibitor of ATAxia telangiectasia and Rad3 related (ATR) kinase with a Ki value of less than 150 pM. VX-803 (M4344) effectively inhibits ATR-driven phosphorylated checkpoint kinase-1 (P-Chk1) phosphorylation with an IC50 value of 8 nM. VX-803 (M4344) has potential antitumor activity. | ||
| M11251 | Gartisertib | ATM/ATR |
| VX-803; M4344; ATR inhibitor 2 | ||
| Gartisertib (VX-803) is an ATP-competitive, orally active, selective ATR inhibitor with Ki<150 pM. Gartisertib inhibits atR-driven phosphorylation of checkpoint kinase-1 (Chk1) with an IC50 value of 8 nM. It has antitumor activity. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
